Key Highlights
- Third-quarter 2026 total net revenues were USD 10.5 million, against USD 13.8 million.
- Operating loss was USD 0.8 million, against USD 2.2 million a year earlier.
- Pharmacy contract Revenue was USD 2.4 million, against USD 0.6 million.
- The company ended the quarter with USD 11.2 million in cash.
NextPlat (NASDAQ:NXPL) reported third-quarter 2026 revenue of USD 10.50 million, against an estimate of USD 13.00 million. Loss per share was USD 0.28, against an estimate of USD 0.46. The company operates a healthcare segment centered on pharmacy services and an E-commerce segment that includes satellite connectivity products.
On the call, management said the third-quarter results reflect its efforts to refocus the Business toward higher-margin contracted healthcare services, with improvements across margins and a reduction in operating losses.
Healthcare Segment
Total net revenues for the quarter were USD 10.5 million, against USD 13.8 million in the prior-year period. Within healthcare, third-quarter revenue was USD 6.7 million, against USD 10.1 million in the third quarter of 2025. Pharmacy contract revenue was USD 2.4 million, against USD 0.6 million, driven primarily by a USD 1.6 million increase in 340B contract revenue. Management said quarterly contracted pharmacy revenues increased nearly 300% from year-ago levels, reflecting new customers secured in late 2025 and early 2026.
On a sequential basis, management said contracts with medication fulfillment facilities declined by approximately USD 0.3 million because a customer closed one of the two facilities the company serves. It said total pharmacy prescription revenue was down year over year, primarily reflecting lower payer reimbursement rates, prescription Volume decreases and payer mix, which it described as pressures affecting independent retail pharmacies broadly.
During the third quarter, the company secured three new 340B contracts, bringing the annual total to 14. Management said onboarding of 340B entities can take around 90 days on average before initial prescriptions are received.
Acquisition and Satellite Business
The company purchased Scott's Pharmacy in Pensacola on October 1 in an all-cash transaction of USD 1.5 million. Management said the operation has performed well since the purchase, with margins ahead of its expectations, and that, based on current activity levels, it contributes approximately USD 1.2 million in quarterly revenues and USD 150,000 in net profits during the fourth quarter. It also cited incremental contributions from its recently opened Jacksonville location.
In its satellite connectivity business, management said it generated sales from customers in more than 115 countries and produced record levels of recurring airtime contract revenue. It also referred to a new online healthcare marketplace and consumer-focused sales channels with Decathlon.
Margins, Liquidity and Management Commentary
Consolidated Gross Profit was USD 3.7 million, against USD 2.7 million in the prior-year period. Consolidated gross Margin was 35%, against nearly 20% a year earlier. Operating expenses were USD 4.5 million, a decrease of about 10% from USD 5 million in the third quarter of 2025 and down from USD 4.8 million in the second quarter of 2026. Salaries, wages and payroll taxes declined about 12% to USD 2.3 million. Operating loss was USD 0.8 million, against USD 2.2 million, a reduction of nearly 65% as stated by management.
The company ended the quarter with USD 11.2 million in cash, against USD 11.9 million in the second quarter. Management attributed the slight sequential decline primarily to an increase in professional fees and public company expenses. During the fourth quarter, the company began selling shares under the at-the-market program established in May, raising over USD 140,000 in net proceeds. Management said the company has no meaningful debt, and that the cash purchase of Scott's Pharmacy reduces the quarterly cash balance.
Management said it recognizes there is Volatility in the healthcare segment, especially in retail, and that it is focused on both organic growth and acquisitions. In response to a Shareholder question, it said it continues to see interest from pharmacy operators inside and outside Florida and pursues only opportunities that meet its requirements for revenue, margins and profitability. It said it announces developments when they occur.






Please wait processing your request...